Last reviewed · How we verify
Administration of Lotemax
At a glance
| Generic name | Administration of Lotemax |
|---|---|
| Sponsor | University of Rochester |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Instillation site discomfort
- Steroid induced intraocular pressure elevation
Key clinical trials
- Loteprednol Etabonate Versus Prednisolone Acetate for Anterior Chamber Granulomas (PHASE4)
- The Role of Loteprednol in Reducing Post-Intravitreal Injection Related Pain (NA)
- Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection (PHASE4)
- The Utility of IVCM to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With DED (PHASE4)
- Comparing Treatment of Dry Eye With Intracanalicular Dexamethasone, Restasis, and/or Lotemax (PHASE4)
- Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization (PHASE3)
- DEXTENZA Therapy for Treatment of Allergic Conjunctivitis (PHASE4)
- The DEPOT Study (Dry Eye Prescription Options for Therapy) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |